MedTrace Logo

Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects

NCT07110740 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-08

No results posted yet for this study

Summary

A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Evaluate Bioequivalence After Dry-powder Inhalation of UIC202005 or UI009 in Healty Volunteers

Conditions

  • Health

Interventions

DRUG

UI009

inhale UI009 twice a day on Day 1 and Day 8.

DRUG

UIC202005

inhale UIC202005 twice a day on Day 1 and Day 8.

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-24
Primary Completion
2024-11-29
Completion
2024-12-13

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07110740 on ClinicalTrials.gov